Back to discover

Protein / target

RNA-binding protein EWS

Encoded byEWSR1Q01844Homo sapiensSwiss-Prot
UniProt: Q01844Ensembl: ENSG00000182944HGNC: HGNC:3508NCBI Gene: 2130
Small-molecule tractable
Druggability
High-Quality Ligand
2
Research papers

Protein at a glance

Biological role

Transcription coregulator

Strongest disease association

Sarcoma, Ewing

Via encoding gene EWSR1 · Genetic literature evidence · score 0.61

Research activity

Emerging research

2 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3'.

View complete UniProt function annotation

Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). Might normally function as a transcriptional repressor (PubMed:10767297). EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes

Subcellular location

NucleusCytoplasmCell membrane
Domains and Gene Ontology detail (13)

Domains & features

IQRRM

Gene Ontology

  • Ccytoplasm
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane
  • Fcalmodulin binding
  • Fidentical protein binding
  • FRNA binding
  • Ftranscription coregulator activity
  • Fzinc ion binding
  • PDNA-templated transcription
  • Pregulation of DNA-templated transcription

656 aa · 68 kDa · 6 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). Might n…
  • ·transcription coregulator activity
  • ·DNA-templated transcription
  • ·regulation of DNA-templated transcription

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene EWSR1

Gene-level evidence surfaced through the gene EWSR1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Sarcoma, Ewing
0.61Moderately supported

Genetic literature evidence dominant · Open Targets 0.41

Sarcoma, Clear Cell
0.43Limited support

Somatic mutation evidence dominant · Open Targets 0.38

Rhabdomyosarcoma
0.41Limited support

Somatic mutation evidence dominant · Open Targets 0.38

Liposarcoma
0.41Limited support

Somatic mutation evidence dominant · Open Targets 0.38

Neurodegenerative Diseases
0.32Preliminary

Pathway evidence dominant · Open Targets 0.47 · no direct causal or clinical evidence

View evidence synthesis (5)
Sarcoma, EwingModerately supported
0.61
agreement 0.50–0.73
Genetic literature65%Literature20%Somatic mutation16%Geneticdup

Open Targets aggregate 0.41 · 3 independent evidence families · 1 not counted as duplicate

Sarcoma, Clear CellLimited support
0.43
agreement 0.27–0.59
Somatic mutation88%Literature12%

Open Targets aggregate 0.38 · 2 independent evidence families

RhabdomyosarcomaLimited support
0.41
agreement 0.25–0.57
Somatic mutation93%Literature7%

Open Targets aggregate 0.38 · 2 independent evidence families

LiposarcomaLimited support
0.41
agreement 0.25–0.57
Somatic mutation94%Literature6%

Open Targets aggregate 0.38 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary
0.32
agreement 0.14–0.50
Pathway94%Literature7%

Open Targets aggregate 0.47 · 2 independent evidence families · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.47
Sarcoma, Ewing0.41
Sarcoma, Clear Cell0.38
Rhabdomyosarcoma0.38
Liposarcoma0.38

Tractability

Small molecules — Emerging

Feasibility evidence (high-quality ligand) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc med conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · High-Quality LigandAB · UniProt loc high confAB · GO CC med confPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Ewing's Sarcoma.274 cites

Riggi N · The New England journal of medicine · 2021

Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment.31 cites

Wrenn ED · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

Recent

Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment.

Wrenn ED · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

Ewing's Sarcoma.

Riggi N · The New England journal of medicine · 2021

Europe PMC papers linked directly to this protein.